Abstract
Background and Aims: Severe hypertriglyceridemia (sHTG; fasting triglycerides ≥500 mg/dL) is a causal risk factor for acute pancreatitis. This phase 2 study (NCT03452228) evaluated efficacy and safety of evinacumab, an investigational angiopoietin-like protein 3 inhibitor, in patients with sHTG who had ≥1 prior hospitalization for acute pancreatitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
